Cardiac αVβ3 integrin expression following acute myocardial infarction in humans

Heart. 2017 Apr;103(8):607-615. doi: 10.1136/heartjnl-2016-310115. Epub 2016 Dec 7.

Abstract

Objective: Maladaptive repair contributes towards the development of heart failure following myocardial infarction (MI). The αvβ3 integrin receptor is a key mediator and determinant of cardiac repair. We aimed to establish whether αvβ3 integrin expression determines myocardial recovery following MI.

Methods: 18F-Fluciclatide (a novel αvβ3-selective radiotracer) positron emission tomography (PET) and CT imaging and gadolinium-enhanced MRI (CMR) were performed in 21 patients 2 weeks after ST-segment elevation MI (anterior, n=16; lateral, n=4; inferior, n=1). CMR was repeated 9 months after MI. 7 stable patients with chronic total occlusion (CTO) of a major coronary vessel and nine healthy volunteers underwent a single PET/CT and CMR.

Results: 18F-Fluciclatide uptake was increased at sites of acute infarction compared with remote myocardium (tissue-to-background ratio (TBRmean) 1.34±0.22 vs 0.85±0.17; p<0.001) and myocardium of healthy volunteers (TBRmean 1.34±0.22 vs 0.70±0.03; p<0.001). There was no 18F-fluciclatide uptake at sites of established prior infarction in patients with CTO, with activity similar to the myocardium of healthy volunteers (TBRmean 0.71±0.06 vs 0.70±0.03, p=0.83). 18F-Fluciclatide uptake occurred at sites of regional wall hypokinesia (wall motion index≥1 vs 0; TBRmean 0.93±0.31 vs 0.80±0.26 respectively, p<0.001) and subendocardial infarction. Importantly, although there was no correlation with infarct size (r=0.03, p=0.90) or inflammation (C reactive protein, r=-0.20, p=0.38), 18F-fluciclatide uptake was increased in segments displaying functional recovery (TBRmean 0.95±0.33 vs 0.81±0.27, p=0.002) and associated with increase in probability of regional recovery.

Conclusion: 18F-Fluciclatide uptake is increased at sites of recent MI acting as a biomarker of cardiac repair and predicting regions of recovery.

Trial registration number: NCT01813045; Post-results.

MeSH terms

  • Aged
  • Anterior Wall Myocardial Infarction / diagnostic imaging
  • Anterior Wall Myocardial Infarction / metabolism*
  • Anterior Wall Myocardial Infarction / pathology
  • Anterior Wall Myocardial Infarction / physiopathology
  • Biomarkers / metabolism
  • Case-Control Studies
  • Contrast Media / administration & dosage
  • Female
  • Humans
  • Inferior Wall Myocardial Infarction / diagnostic imaging
  • Inferior Wall Myocardial Infarction / metabolism*
  • Inferior Wall Myocardial Infarction / pathology
  • Inferior Wall Myocardial Infarction / physiopathology
  • Integrin alphaVbeta3 / metabolism*
  • Magnetic Resonance Imaging
  • Male
  • Middle Aged
  • Myocardium / metabolism*
  • Myocardium / pathology
  • Peptides
  • Polyethylene Glycols
  • Positron Emission Tomography Computed Tomography
  • Recovery of Function
  • ST Elevation Myocardial Infarction / diagnostic imaging
  • ST Elevation Myocardial Infarction / metabolism*
  • ST Elevation Myocardial Infarction / pathology
  • Time Factors
  • Ventricular Function, Left
  • Ventricular Remodeling

Substances

  • AH 111585
  • Biomarkers
  • Contrast Media
  • Integrin alphaVbeta3
  • Peptides
  • Polyethylene Glycols

Associated data

  • ClinicalTrials.gov/NCT01813045